SARS-CoV-2 Testing Solutions for Laboratories
Cookies on PerkinElmer
PerkinElmer uses cookies to ensure that we give you the best experience possible on our website. This may include cookies from third party websites. If you continue without changing your settings, we will assume that you consent to receive cookies from this website. You can change your cookie settings at any time. To learn more, please review our cookie policy, which includes information on how to manage your cookies.

Solutions for SARS-CoV-2 Detection

SARS-CoV-2 Detection

We are here to help laboratories overcome their SARS-CoV-2 testing challenges so they can better address the world’s urgent public health concerns. We are working closely with laboratories around the world to deliver the nucleic acid isolation, automation, real-time PCR, antibody testing, and vaccine development solutions they need to rapidly respond to these challenges. Our top priority is to provide the technology and support to meet these needs.


Explore our SARS-CoV-2 Testing Products

SARS-CoV-2 Real-time RT-PCR Assay

PerkinElmer® SARS-CoV-2 Real-time RT-PCR Assay

The PerkinElmer® SARS-CoV-2 Real-time RT-PCR assay is CE-IVD marked and intended for in vitro diagnostic use in Europe. This assay provides reliable and high-quality results for the clinical detection of COVID-19 in human oropharyngeal swab, nasopharyngeal swab, bronchoalveolar lavage (BAL), sputum, plasma or serum samples.

Learn More

PerkinElmer® GSP®/DELFIA® Anti-SARS-CoV-2 IgG Kit CE-IVD

PerkinElmer® GSP®/DELFIA® Anti-SARS-CoV-2 IgG Kit CE-IVD

The PerkinElmer® GSP®/DELFIA® Anti-SARS-CoV-2 IgG kit delivers qualitative detection of human IgG antibodies against SARS-CoV-2 in dried blood spots (DBS), plasma, and serum to identify individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.

Automated, high-throughput processing of DBS is available with the GSP® instrument.

Manual processing of plasma and serum samples is available with the VICTOR2 D instrument.

Learn More

Remote Services

Remote Services

Resolve instrument repairs faster and increase uptime. OneSource remote options do just that. Remote Support and Radian Remote Diagnostic services.

Learn More

See How Fast We Can Fulfill Your SARS-CoV-2 Testing Needs
PerkinElmer is extending support to mitigate the issue by providing a live stream of RT-PCR test and automated RNA extraction equipment lead time for setting up labs.

Webinar

Improve the Efficiency of Coronavirus Testing

This is a challenging time for laboratories working on the front lines of COVID-19 pandemic. In this webinar, we will describe how PerkinElmer is helping the community address this urgent public health concern. We will share details on immediately deployable solutions that can equip labs with viral nucleic acid isolation set up, extraction and detection to efficiently process thousands of tests every day.

Speakers

Arvind.jpg

WebinarBioHeadshot-Christine.jpg

Blog Posts


Anterior Nasal Swabs for COVID-19 Testing

Anterior Nasal Swabs for COVID-19 Testing

The FDA has authorized a new sample type, anterior nasal swabs, for use with some EUA authorized real-time RT-PCE assays for COVID-19 testing. Using anterior nasal swabs for SARS-CoV-2 testing offers many advantages over the typical sample types, human oropharyngeal and nasopharyngeal swab samples.

Read More






Importance of Immunoassays for Coronavirus Control

Importance of Immunoassays for Coronavirus Control

On December 31, 2019, a pneumonia case in the Chinese city, Wuhan, with unknown pathological origin, was reported into the Chinese World Health Organization (WHO) office. By March 11, 2020, the virus had spread to 114 countries and had taken nearly 4,300 lives leading WHO to declare COVID-19 a global pandemic (WHO, 2020).

Read More





How to Handle Inconclusive Samples with SARS-CoV-2 Real-Time PCR Tests

How to Handle Inconclusive Samples with SARS-CoV-2 Real-Time PCR Tests

SARS-CoV-2 real-time reverse transcription polymerase chain reaction (RT-PCR) tests, can be inaccurate in two ways, as can all diagnostic assays. A false-positive result mistakenly identifies a person as infected, resulting in unnecessary quarantine and contact tracing. False-negative results are far more problematic because infected people may not isolate themselves and can infect others.

Read More




Choosing a SARS-CoV-2 Real-Time RT-PCR Assay

Choosing a SARS-CoV-2 Real-Time RT-PCR Assay

Accurate detection of SARS-CoV-2 is critical for both patient treatments, as well as control of the COVID-19 pandemic. Many factors need to be considered when choosing a workflow to use for SARS-CoV-2 detection.

Read More







Ensuring the Accuracy of your SARS-CoV-2 Testing Results

Ensuring the Accuracy of your SARS-CoV-2 Testing Results

Accuracy of SARS-CoV-2 testing is critical when determining if someone is infected and needs to be quarantined and/or treated for a coronavirus infection. Real-time reverse transcription polymerase chain reaction (RT-PCR) assays are the tool of choice for determining if someone has an active viral shedding of SARS-CoV-2. RT-PCR assays reverse transcribe the viral RNA into DNA for amplification and subsequent identification of target regions.

Read More





Significance & Difference between Target Regions for SARS-CoV-2 Testing

Significance & Difference between Target Regions for SARS-CoV-2 Testing

Severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2, the virus responsible for the disease known as COVID-19, is now a global pandemic.  This novel coronavirus was first observed in humans in December of 2019 and sequenced by multiple teams over the next month (Wu et al., 2020; Zhu et al., 2020; Chan et al., 2020).

Read More






Helping Labs Test for COVID-19

Helping Labs Test for COVID-19

The CDC limits IRR’s SARS-CoV-2 diagnostic reagent distribution to US state and/or local labs qualified to perform seasonal influenza surveillance testing and to local labs approved by their state public health laboratory to perform SARS-CoV-2 testing. Only CLIA facilities with appropriate equipment, training, and demonstration of testing proficiency can be considered.

Read More


Press Releases


PerkinElmer Releases New Dried Blood Spot Based COVID-19 Serology Test

WALTHAM, Mass.--(BUSINESS WIRE)--Jul. 21, 2020-- PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced the launch of a dry blood spot (DBS) based test for SARS-CoV-2 IgG using its GSP®/DELFIA® platform, enabling processing of up to 5,000 samples per day.

Read More

Sonora Quest Collaborates with State and Health Care Leaders to Vastly Expand COVID-19 Testing Capacity in Arizona

July 9, 2020 PHOENIX — Governor Doug Ducey announced today a strategic collaboration with Sonora Quest Laboratories, the market share leader in diagnostics laboratory testing in Arizona, the Arizona Department of Health Services (ADHS) and PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, to expand testing in Arizona. The collaboration helps catapult COVID-19 diagnostic testing capacity well ahead of the significant demand in Arizona.

Read More

Global Collaboration Establishes Wales’ National Covid-19 Testing Laboratory

An advanced laboratory dedicated to leading Wales’ national Covid-19 testing has been established in Cardiff, thanks to collaboration between Public Health Wales and one of the world’s leading diagnostics companies.

Read More

FDA Provides Emergency Use Authorization to PerkinElmer for COVID-19 Testing

WALTHAM, Mass.--(BUSINESS WIRE)--Mar. 24, 2020-- PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that the U.S. Food and Drug Administration (FDA) has provided Emergency Use Authorization (EUA) for the Company’s New Coronavirus RT-PCR test.

Read More

EUROIMMUN is one of first European manufacturers of diagnostic testing to provide CE-marked antibody detection systems to support COVID-19 diagnostics

The Anti-SARS-CoV-2 ELISAs for immunoglobulin classes A and G from EUROIMMUN, a PerkinElmer, Inc. company (NYSE:PKI), have received the CE mark and can now be applied to COVID-19 diagnostics. The PCR test EURORealTime SARS-CoV-2 has been submitted for CE mark.

Read More

FDA Provides Emergency Use Authorization to PerkinElmer for Serological Test to Identify COVID-19 Antibodies

WALTHAM, Mass.--(BUSINESS WIRE)--May 5, 2020-- PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that the U.S. Food and Drug Administration (FDA) has provided Emergency Use Authorization (EUA) for EUROIMMUN’s (a PerkinElmer company) Anti-SARS-CoV-2 ELISA (IgG) serology test.

Read More

Accelerate Your SARS-COV-2 Testing